SynVista Therapeutics, Inc. (SYNI)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

221 WEST GRAND AVENUE MONTVALE,, NJ 07645

Alteon is a product-based biopharmaceutical company engaged primarily in the development of small molecule drugs to treat and prevent cardiovascular disease and diabetes. As of Dec 31 2006, Co.'s lead drug candidate, alagebrium chloride or alagebrium (formerly ALT-711), was a glycation end-product (A.G.E.) crosslink breaker being developed for diastolic heart failure (DHF). In addition, Co. has expanded its portfolio with another compound in Phase II clinical development for cardiovascular complications of diabetes through its Jul 2006 acquisition of HaptoGuard, Inc.

View SEC Filings from SYNI instead.

View recent insider trading info

Funds Holding SYNI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SYNI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BERKOWITZ NOAH PRESIDENT & CEO

  • Officer
  • Director
  • 10% Owner
0 2008-12-01 0

MENDEL CARL M VP & CHIEF MEDICAL OFFICER

  • Officer
0 2008-12-01 0

D'AMICO ALEX PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2008-12-01 0

MILICI WENDY ANN DIRECTOR OF FINANCE

  • Officer
0 2008-12-01 0

FEDERICI WILLIAM J

  • Director
0 2008-10-06 0

YETTER WAYNE P.

  • Director
0 2008-07-22 0

TANNER MARY C

  • Director
0 2008-07-22 0

BEDARD JOHN F.

  • Director
0 2008-07-22 0

ATTICUS CAPITAL LP

ATTICUS MANAGEMENT LTD

BARAKETT TIMOTHY R

  • 10% Owner
0 2007-07-25 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments